Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MAGE family member E2 (MAGEE2)
- Target
- MAGEE2
- Molecular classification
- Other (Cancer-testis antigen family; specifically, the E-type subfamily of MAGE proteins)[5][7]
01
Overview
MAGE family member E2 (MAGEE2) is a protein encoded by the intronless MAGEE2 gene, part of the E-type subfamily of the MAGE (melanoma antigen-encoding gene) family. The MAGE proteins are characterized by the MAGE homology domain and interact with E3 ubiquitin ligases, influencing protein stability and cell signaling, with important roles in tumorigenesis. MAGEE2 has been associated with melanoma and hepatocellular carcinoma and may play roles in transcriptional processes and brain development, particularly in rodents. While extensively studied in the context of cancer-testis antigens, specific therapeutic targeting and unique mechanistic details for MAGEE2 remain less well-defined relative to other MAGE family members[5][7][1][2][3][4].
- Other names
- Melanoma-associated antigen E2HCA3Hepatocellular carcinoma-associated protein 3MAGE-E2 antigen
02
Mechanism of action
As a member of the MAGE family, may act by influencing the activity of E3 ubiquitin ligases, impacting protein ubiquitination and degradation in cancer cells (e.g., impacting p53, as seen in other MAGEs)[1]
03
Biological functions
Potential modulation of transcriptional regulation[3]May interact with ubiquitin E3 ligase complexes, general to MAGE family[1]Possible role in brain morphogenesis (supported in mouse ortholog)[2][4]
04
Disease associations
Cancer (notably melanoma, hepatocellular carcinoma, and other malignancies as part of the MAGE family)[5][1]
05
Safety considerations
As with other MAGE cancer-testis antigens, on-target off-tumor toxicity is a theoretical concern if targeted due to potential expression in some normal tissues; detailed expression for MAGEE2 in normal tissues is poorly characterized[6]
06
Biomarkers
The broader MAGE family, including MAGEE2, is considered a cancer-testis antigen and may act as a biomarker for certain cancers (e.g., its family members are linked to poor prognosis and induction/recurrence in multiple cancers)[1]
Beyond the preview
Go deeper on MAGE family member E2 (MAGEE2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAGE family member E2 (MAGEE2).